Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
167.99B
Market cap167.99B
Price-Earnings ratio
42.03
Price-Earnings ratio42.03
Dividend yield
5.85%
Dividend yield5.85%
Average volume
41.34M
Average volume41.34M
High today
$29.72
High today$29.72
Low today
$28.98
Low today$28.98
Open price
$29.59
Open price$29.59
Volume
16.86M
Volume16.86M
52 Week high
$31.44
52 Week high$31.44
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $29.48. The company's market cap stands at 167.99B, with a P/E ratio of 42.03 and a dividend yield of 5.85%.

On 2026-11-09, Pfizer(PFE) stock moved within a range of $28.98 to $29.72. With shares now at $29.48, the stock is trading +1.7% above its intraday low and -0.8% below the session's peak.

Trading activity shows a volume of 16.86M, compared to an average daily volume of 41.34M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

PFE News

The Motley Fool 3h
Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

There are advantages to being the first mover in a market, but that doesn't mean that a company can't enter later on and still succeed, and even be a dominant p...

Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
Simply Wall St 13h
Pfizer Lifts Guidance Following Pipeline Wins While Fair Value Looks Near Reach

Pfizer (PFE) just lifted its 2026 revenue guidance by US$1.5b to a range of US$62b to US$64b, a move that puts earnings expectations, cancer drugs, and AI partn...

Pfizer Lifts Guidance Following Pipeline Wins While Fair Value Looks Near Reach
The Motley Fool 2d
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

Eli Lilly (LLY -0.79%) is much loved on Wall Street because of its highly successful GLP-1 weight-loss business. Novo Nordisk (NVO +0.03%) is much less apprecia...

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

Analyst ratings

60%

of 30 ratings
Buy
30%
Hold
60%
Sell
10%

More PFE News

Simply Wall St 2d
Pfizer Plans $650 Million Connecticut Center For Clinical Drug Production

Pfizer (NYSE:PFE) plans to invest US$650 million in a new manufacturing technology center at its Connecticut R&D campus. The facility is intended to produce cl...

Pfizer Plans $650 Million Connecticut Center For Clinical Drug Production
TipRanks 3d
Pfizer Earnings Call Signals Growth Beyond COVID Headwinds

Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S ((TSE:PFE)) has held its Q3 earnings call. Read on for the main highlights of the call....

24/7 Wall St. 3d
Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Investing Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027? A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales,...

Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
TipRanks 3d
Pfizer Advances Monthly Sleep Apnea Drug Study as Investors Watch Its Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer’s Phase 3 study, officially titled “A PHASE 3, RANDOMIZED, DOUBLE-...

TipRanks 3d
Pfizer Advances Monthly Obesity Drug Study in China

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer’s Phase 3 study, titled “A Phase 3, Randomized, Double-Blind, Placebo-Controlled S...

TipRanks 3d
Pfizer Advances Early Berobenatide Delivery Study in Obesity Drug Race

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer’s recruiting Phase 1 study, officially titled “PHASE 1, SINGLE DOSE, OPEN-LABEL, R...

TipRanks 3d
Pfizer Advances Phase 3 RSV Vaccine Study in High-Risk Children

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer’s NCT07839871, titled “A Phase 3 Study to Evaluate the Safety, Tolerability, and I...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.